VAXIMM, 다수의 해외 과학 및 산업 이벤트 참가 예정

NEXT STORY
Outlook on the mRNA Vaccines and Therapeutics Global Market to 2031 – Growing Emphasis on R&D for Non-COVID-19 Applications Presents Opportunities
PREV STORY
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Medivir’s Nomination Committee proposes new Board of Directors ahead of 2016 AGM

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced the Nomination Committee’s proposal ...

author_avatar
NASDAQ Market News

Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition (Tremfya®*)

ARROW study to assess the mechanistic superiority of direct IL-17A inhibition (Cosentyx) over IL-23 ...

author_avatar
NASDAQ Market News

CytomX to Present at the Jefferies 2017 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 25, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), ...

author_avatar
NASDAQ Market News